One of the challenges of managing an information oriented site like this one is how best to speak to a wide variety of readers, all with very personal needs and interests. Become too technical and you keep experienced survivors happy at the expense of those who desperately need information most--those who have been recently diagnosed--or
While I was researching my pre-ASH article on our Help With Cancer.org site this morning (that is where I post non-myeloma related cancer news from large oncology conferences like ASH and ASCO), I found this interesting tidbit burried deep in one of Pfizer's press releases:A Phase 1 trial evaluating PD 0332991 in combination with bortezomib
Experimental Ovarian Cancer Drug, ENMD-2076, May Work Against Acute Myeloid Leukemia & Multiple Myeloma Too!
Here is another pre-ASH press release from PRNewswire.com:ENMD-2076 Phase 1 Data in Hematological Studies to be Presented at ASHENMD-2076 Multiple Myeloma and Leukemia Abstracts to be Published in BloodROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall:EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2
Here is a research abstract, published in Blood, testing the viability of one of the new kinase inhibitors:Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor Bao Hoang1, Patrick Frost1, Yijiang Shi1, Eileen Belanger1, Angelica Benavides1, Gholam Pezeshkpour2, Susanna Cappia3, Tommasina Guglielmelli3, Joseph Gera1 and Alan Lichtenstein1,* 1 Division of Hematology Oncology, UCLA-Greater
New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma
The Journal of New England Technology ran this article Friday:MMRC joins UK biotech in start of multiple myeloma trialA Phase 2 clinical trial of a treatment for relapsed or refractory multiple myeloma has launched, led by U.K.-based Astex Therapeutics Ltd. and funded by Norwalk, Conn.-based Multiple Myeloma Research Consortium (MMRC). Noopur Raje, of the Massachusetts
Here is a link to a British study abstract about another new, anti-myeloma drug:EntreMed’s ENMD-2076 Demonstrates Significant Anti-Cancer Activity in Multiple Myeloma Preclinical Models.The study results were published in the British Journal of Haematology.ENMD-2076 is another variation of a kinase inhibitor. Lots of research going on worldwide using kinase inhibitors against multiple myeloma. Hopefully some